

# Index

## A

- Abdominal compartment syndrome (ACS), 215
- ACE inhibitor. *See* Angiotensin converting enzyme (ACE) inhibitors
- ACE receptor blockers (ARB), 256
- Acetazolamide, 155
- N*-Acetylcysteine, contrast induced nephropathy, 210
- Acid–base disorders
- complex, 158
  - mixed
    - case study, 157, 158, 161–162
    - complex disorders, 158
    - diagnosis, 158–161
    - Henderson–Hasselbalch equation, 157
    - stepwise approach, 158–161
- Acid–base disturbances
- chronic kidney disease, 257–258
  - potassium balance, 88
- Acidemia, 120
- Acquired nephrotic syndrome, 35–36
- Acromegaly, 526–527
- Acute coronary syndrome
- presentation and findings, 540
  - treatment, 541
- Acute decompensated heart failure (ADHF), 225–228
- Acute dialysis quality initiative (ADQI), 166
- Acute fatty liver of pregnancy (AFLP), 596–597
- Acute interstitial nephritis (AIN), 168, 203
- Acute kidney injury (AKI), 192
- ARF, 165
  - case study, 165, 167, 172, 542
  - causes of, 167
  - complications, 171
  - definition of, 166
  - diagnosis of, 169–171
  - epidemiology, 166
  - etiologies
    - cardiorenal syndrome, 224–228 (*see also* Cardiorenal syndrome (CRS))
    - contrast induced nephropathy, 206–211 (*see also* Contrast induced nephropathy (CIN))
    - drugs/nephrotoxins, 199–206 (*see also* Drug and toxin induced nephrotoxicity)
    - hepatorenal syndrome, 211–219 (*see also* Hepatorenal syndrome (HRS))
    - tumor lysis syndrome, 219–224 (*see also* Tumor lysis syndrome (TLS))
  - glomerular injury, 168–169
  - interstitial injury, 168
  - intratubular obstruction, 169
  - management, 171
    - acid–base implications of fluids, 239
    - case study, 237
    - conservative management, 238
    - crystalloid vs. colloid, 239
    - diuretics, 240
    - extracellular volume, expand of, 238–239
    - hemodynamic status, 238, 240, 242–244
    - nutritional goals, 241
    - prerenal, 238
    - renal replacement therapy, 241–245
    - transfusion, 239
    - vasopressors, 240
    - volume resuscitation, 239
    - volume status, assessment, 238–239
  - pathophysiology, 167–169
  - postrenal, 168
  - prerenal azotemia, 167–168, 176, 179
  - presentation and findings, 541
  - preventive measures, 171–172
  - prognosis, 171
  - staging system, 166
  - treatment, 542
  - tubular injury, 168
  - urinary tract obstruction, 185, 186, 188
  - vascular injury, 169
- Acute kidney injury network (AKIN), 166
- Acute renal failure (ARF), 165
- Acute tubular necrosis (ATN), 200, 204, 205, 214, 215
- case study, 191, 196–197
  - diagnosis
    - biomarkers, 194
    - BUN and serum creatinine, 194

- Acute tubular necrosis (ATN) (*cont.*)  
 history and physical examination, 193–194  
 renal biopsy, 194–195  
 risk factors for, 194  
 ultrasound, 194  
 urinalysis, 194  
 differential diagnosis, 195  
 early prediction/prevention, 196  
 etiology, 192  
 management, 195, 196  
 pathophysiology  
 inflammation, 193  
 tubular changes, 193  
 vascular abnormalities, 192–193  
 prognosis, 195–196  
 Acute uric acid nephropathy, 602  
 ADQI. *See* Acute dialysis quality initiative (ADQI)  
 Adrenal adenoma, 521, 522, 529  
 Advanced glycation end-products (AGEs), 550  
 Adynamic bone disease, 264  
 AGEs. *See* Advanced glycation end-products (AGEs)  
 Aging, CKD  
 case study, 315, 320  
 functional status, 318–319  
 morbidity and mortality, 318  
 renal replacement therapy, 319–320  
 senescence kidney, 316  
 structural and histological changes, 316  
 AIN. *See* Acute interstitial nephritis (AIN)  
 AKI. *See* Acute kidney injury (AKI)  
 AKIN. *See* Acute kidney injury network (AKIN)  
 AL-Amyloidosis, 624–625, 627  
 Albumin, hepatorenal syndrome, 218  
 Albumin-to-creatinine ratio, 20  
 Albuterol (Salbutamol), for hyperkalemia, 98  
 Alcohol, 510–511  
 Aldosterone, 89, 94, 95  
 Alemtuzumab, 402  
 Alkalemia  
 acid–base disorders, 159  
 definition of, 152  
 diagnosis, 154  
 Alkalosis, definition of, 151  
 Allopurinol, 647, 648, 651, 652, 656  
 for tumor lysis syndrome, 222–223  
 Alport syndrome (AS), 44, 615–616  
 Alveolar hyperventilation, respiratory alkalosis, 151, 152  
 Alveolar hypoventilation, respiratory acidosis, 143–144  
 American College of Radiology, 208  
 American College of Rheumatology (ACR), 551–553,  
 565–566  
 criteria, ANCA-associated vasculitis, 70  
 Aminoglycosides, acute tubular necrosis, 192, 195  
 ANA. *See* Antinuclear antibodies (ANA)  
 ANCA-associated vasculitis (AAV), serologic testing  
 Churg–Strauss syndrome (CSS), 70  
 and disease flares, 71–72  
 ELISA, 71  
 immunofluorescence (IIF), 71  
 microscopic polyangiitis (MPA), 70  
 polyarteritis nodosa (PAN), 70  
 renal-limited vasculitis (RLV), 70  
 Wegener’s granulomatosis (WG), 70  
 Anemia, CKD, 257, 276, 277  
 ACE inhibitors, 276  
 adjuvant therapy, 282, 284  
 case study, 275, 280–281, 284  
 causes of, 290  
 clinical manifestations, 276  
 correction, 290  
 darbepoetin, 276, 278–279  
 definition, 275  
 diagnosis of, 275–276  
 erythropoietin stimulating agent (ESA)  
 continuous erythropoietin receptor activators,  
 278, 279  
 dosing guidelines, 278  
 hyporesponsiveness, 279  
 side effects, 280  
 use of, 278–280  
 iron deficiency (*see* Iron deficiency anemia)  
 KDOQI guidelines, 275, 282  
 prevalence, 275–276, 290  
 reticulocyte count, 276  
 treatment of  
 CHOIR Study, 277  
 CREATE Study, 277–278  
 meta-analysis, 278  
 Normal Hematocrit Study, 277  
 TREAT Study, 278  
 Angiotensin converting enzyme (ACE) inhibitors,  
 256, 482–484, 489, 528, 529, 585  
 Angiotensin-II, potassium disorders, 93–95  
 Angiotensin receptor blocker (ARB), 484, 485  
 Anion gap, metabolic acidosis, 125–126  
 Antegrade and retrograde pyelography, urinary tract  
 obstruction, 188  
 Anti-chromatin antibodies, 566  
 Anti-C1q antibodies, 72–73, 567  
 Antidiuretic hormone (ADH), hyponatremia, 80, 81  
 Anti-glomerular basement membrane (GBM) disease  
 antibodies, 69  
 rapidly progressive glomerulonephritis, 52–53, 56, 57  
 serologic testing, 69  
 Antihypertensive and Lipid-Lowering Treatment to  
 Prevent Heart Attack Trial (ALLHAT), 482  
 Anti-neutrophil cytoplasmic antibody (ANCA), 53, 56  
 disease associations, 71  
 Antinuclear antibodies (ANA), 563  
 Antiphospholipid Ab syndrome (APLS), 73  
 Antiproteinuria, hypertension, 256, 484  
 Antiretroviral therapy, 584–585  
 Anuria, AKI, 165, 168  
 Aortic dissection  
 case study, 540  
 presentation and findings, 539  
 treatment, 539–540  
 Apparent mineralocorticoid excess, 523–524  
 Aquaporin, 609  
 Aquaretics, cardiorenal syndrome, 227

- ARAS. *See* Atherosclerotic renal artery stenosis (ARAS)
- ARB. *See* Angiotensin receptor blocker (ARB)
- Arcila, A., 143
- ARF. *See* Acute renal failure (ARF)
- Arteriography, renal, 27–28
- Arteriovenous fistulas (AVF), hemodialysis, 336, 344
- AS. *See* Alport syndrome (AS)
- ASCT. *See* Autologous stem cell transplantation (ASCT)
- Atherosclerotic renal artery stenosis (ARAS), 520–521
- ATN. *See* Acute tubular necrosis (ATN)
- Autoantibody specificities, in SLE, 565–566
- Autologous stem cell transplantation (ASCT), 628–629
- Automated peritoneal dialysis (APD), 355
- Autosomal dominant polycystic kidney disease
- abdominal CT scan, 608
  - berry aneurysms, 609
  - case study, 617–618
  - clinical manifestations, 607–608
  - dialysis/transplant, 613–614
  - fabry disease, 617–618
  - genetics, 609–610
  - hematuria, 613
  - hereditary nephritis, 614–616
  - hypertension management, 613
  - insulin-like growth factor, 610
  - liver cysts, 609
  - local renal complications, 608
  - management, 611–613
  - pregnancy, 614
  - primary cilium, 610
  - progressive renal dysfunction, 608
  - renal cystic disease, 611–612
  - renal cysts, 610
  - slow progression
    - somatostatin, 613
    - tolvaptan, 613
  - sonographic criteria, 611
  - TBMN, 616–617
- Azathioprine, 404. *See also* Mycophenolate mofetil (MMF)
- Azotemia. *See* Prerenal azotemia
- B**
- Baltimore Longitudinal Study of Aging, 316
- Banff classification, 415
- Barbiturates, 146
- Baroreceptors, hypovolemic hyponatremia, 81
- Basiliximab, 402
- Belatacept, 402
- Benzodiazepines, 146, 147
- Berry aneurysms, 609
- Beta-2 adrenergic agonists, intracellular potassium shift, 98
- Beta blockers, 500, 543, 557
- Beta-2 microglobulin (B2M), 622
- Bisphosphonates, calcium disorders, 108
- BK nephropathy (BKN), 439–440
- BK virus (BKV), 439–442
- BK virus nephritis (BKVN), 464
- Blood gas, metabolic acidosis, 121, 122, 129–130
- Body surface area (BSA), creatinine clearance, 14
- Bohr effect, metabolic acidosis, 123
- Bone disorders, chronic kidney disease, 257
- Bortezomib, 628, 629
- C**
- Caffeine, 511
- Calcific uremic arteriopathy (CUA). *See* Soft tissue calcification
- Calcineurin inhibitor toxicity (CNI), 465
- Calciphylaxis. *See* Soft tissue calcification
- Calcitonin, calcium disorders, 108
- Calcium administration, hyperkalemia, 97–98
- Calcium-alkali syndrome, 138
- Calcium channel blockers (CCBs), 482–485, 489, 500, 557
- Calcium disorders
- bisphosphonates, 108
  - calcitonin, 108
  - case study, 109
  - clinical features, 106
  - complications, 109
  - corrected calcium, 104
  - diagnosis, 106–107
  - differential diagnosis, 107–108
  - diuresis, 108
  - epidemiology, 104
  - etiology/pathophysiology
    - CKD, 105–106
    - hypoparathyroidism, 105
    - milk-alkali syndrome and granulomatous diseases, 105
    - primary hyperparathyroidism and malignancy, 104–105
    - vitamin D deficiency, 105
  - glucocorticoids, 108
  - hypercalcemia, 104–109
  - hypocalcemia, 104–109
  - nephrocalcinosis, 106
  - parathyroid gland, 108
  - prognosis, 109
  - PTH, 104, 107–108
  - vitamin D, 105
- Calcium oxalate, 648
- Calcium oxalate dihydrate crystals, 641
- Calcium phosphate crystals, 641
- Calcium phosphate stones, 648
- CAN. *See* Chronic allograft nephropathy (CAN)
- Cardiac dysrhythmias, hypokalemia, 89
- Cardiorenal syndrome (CRS)
- acute decompensated heart failure, 225–228
  - aquaretics, 227
  - case study, 224–225, 228
  - central venous pressures, 226
  - clinical features, 226
  - definition, 225, 226
  - diagnosis, 226–227
  - diuretics, 227
  - epidemiology, 225

- Cardiorenal syndrome (CRS) (*cont.*)  
 inotropes, 227  
 management, 227  
 natriuretics, 227  
 pathophysiology, 225–226  
 prognosis, 228  
 ultrafiltration, 227–228
- Cardiovascular disease (CVD), 558  
 and chronic kidney disease, 255
- Cast nephropathy, 623
- Casts, in urine, 22–23
- Cation-exchange resins, hyperkalemia, 99–100
- CCBs. *See* Calcium channel blockers (CCBs)
- Central nervous system infection, 453
- Central pontine myelinolysis. *See* Osmotic demyelination syndrome (ODS)
- Chemoreceptors, metabolic acidosis, 123, 124
- Chronic allograft nephropathy (CAN), 465–466
- Chronic kidney disease (CKD), 7, 105, 484  
 ACCOMPLISH trial, 290  
 acidosis, 291  
 aging  
   case study, 315, 320  
   functional status, 318–319  
   morbidity and mortality, 318  
   renal replacement therapy, 319–320  
   senescence kidney, 316  
   structural and histological changes, 316  
 anemia (*see* Anemia, CKD)  
 bicarbonate supplementation, 258  
 birth weight, 254  
 blood pressure management, 289, 290  
 case study, 251, 258–259, 287–288, 294  
 causes of, 288  
 definitions, 251–252  
 description, 287  
 dyslipidemia, 293–294  
 in elderly, 317  
   cystatin C, 317  
   functional status, 318–319  
   glomerular filtration rate measurement, 316, 317  
   hypotension, 319  
   Kidney Disease Outcome Quality Initiative  
     K/DOQI), 315  
   morbidity, 318  
   mortality, 318  
   multidisciplinary care, 318  
   prevalence, 315  
   renal replacement therapy, 319–320  
 ergocalciferol dose repletion, 269  
 ethics  
   advanced care planning (ACP), 311  
   case study, 309–310, 313–314  
   dialysis, initiation of, 310  
   dialysis, withdrawal from, 310–311  
   Emergency Medical Treatment and Active Labor  
     Act, 312  
   end-of-life issues, 311  
   renal transplantation, 313  
   unfunded patients, dialysis in, 312–313  
   GFR, 252  
   history and physical exam, 254  
   hypertensive nephrosclerosis, 289  
   incidence, 288  
   lowering agents, 270, 271  
   metabolic abnormalities, 255  
   microalbuminuria, 288, 291  
   mineral and bone disorder  
     biochemical markers, 263  
     biochemistry, 265–267  
     case study, 263, 272  
     complications, 264  
     KDIGO, 264  
     KDOQI, 264  
     management guidelines, 264  
     monitoring recommendations, 267–268  
     treatment, 268–272  
 modifiable risk factors  
   anemia, 257  
   cardiovascular disease, 255  
   dyslipidemia, 256  
   electrolyte and acid–base disturbances, 257–258  
   glycemic control, 257  
   hypertension, 255–256  
   mineral and bone disorders, 257  
   proteinuria, 256  
   uric acid, 257  
 multidisciplinary CKD clinics (MDC), 254  
 NKF/KDOQI definition, 315, 316  
 non-modifiable risk factors, age, 254–255  
 nutrition  
   assessment methods, 300–301  
   case study, 299–300  
   dietary recommendations, 301, 302  
   minerals and electrolytes, 304–306  
   mortality indicator, 307  
   nutrients, 301, 303–304  
   vitamins, 306  
 obesity, 254, 292  
 prevalence, 263  
 progression rate, 288  
 proteinuria, 291–292  
   evaluation of, 253  
 rennin–angiotensin–aldosterone system management,  
   289, 290  
 risk factors, 255, 288  
 screening for, 252, 254  
 screening intervals and progression management, 258  
 secondary hypertension, 519  
 signs and symptoms of, 254  
 stages of, 252, 253  
 target and goals for advanced stages, 258  
 uric acid role, 292–293
- Chronic Kidney Disease Epidemiology Collaboration  
 (CKD-EPI) equation, 15, 252, 317
- Churg–Strauss syndrome (CSS), 70
- Cigarette smoking, 292
- CIN. *See* Contrast induced nephropathy (CIN)
- Cirrhosis, 178, 180
- CIT. *See* Cold ischemia time (CIT)

- CKD. *See* Chronic kidney disease (CKD)
- Coarctation of aorta, 527–528
- Cocaine, 543
- Cockcroft-Gault equation, 14, 252, 317
- Cold ischemia time (CIT), 464
- Collagen networks, type IV, 615
- Color, of urine, 18
- Complement levels, 54, 56  
nephritic syndrome, 68
- Complex acid–base disorders, 158
- Complications of kidney transplantation. *See* Kidney transplantation, complications of
- Computed tomography (CT), renal  
contrast, 26–27  
noncontrast, 26, 27  
renal cell carcinoma, 27  
urography and angiography, 27
- Congenital adrenal hyperplasia, 524
- Congenital nephrotic syndrome, 35
- Congestive heart failure (CHF), 177, 178, 180
- Conivaptan, hyponatremia, 84
- Continuous ambulatory peritoneal dialysis (CAPD), 355
- Continuous renal replacement therapy (CRRT)  
advantages and disadvantages, 244  
modalities of, 244, 245
- Contrast induced nephropathy (CIN)  
*N*-acetylcysteine, 210  
ascorbic acid, 210  
case study, 206–207, 211  
clinical features, 209  
contrast agent and volume, 209–210  
definition, 207  
differential diagnosis, 209  
fenoldapam, 210  
hemofiltration and hemodialysis, 210  
hydration, 210  
iloprost, 210  
incidence, 207  
nonionic contrast agents, 208  
pathophysiology, 208–209  
prevention, 209  
prognosis, 211  
radiopaque contrast agents, types and properties of, 208  
risk factors for, 207  
risk patients, identification, 208  
risk score, 208  
statins, 210  
theophylline, 210  
treatment, 211
- Cortical necrosis, 601
- Corticosteroids  
maintenance immunosuppression, 404  
rapidly progressive glomerulonephritis, 55
- Creatinine, 6  
renal function, assessment, 12–13
- Creatinine-based estimation formulae, for glomerular filtration rate, 14–15
- Creatinine clearance (CrCl), 14
- Crescentic glomerulonephritis. *See* Rapidly progressive glomerulonephritis (RPGN)
- CRS. *See* Cardiorenal syndrome (CRS)
- Cryoglobulinemia, 581–583  
renal biopsy, 64
- Cryoglobulins, 70
- Crystal induced nephropathies, 203
- Crystalluria, 656
- Crystals, in urine, 23
- Cushing syndrome, 522–523
- CVD. *See* Cardiovascular disease (CVD)
- Cyanosis, 146
- Cyclophosphamide, 569–573  
rapidly progressive glomerulonephritis, 55
- Cyclosporine, 403
- Cystatin C, 15–16
- Cystine crystals, 642
- Cystinuria, 637, 646
- Cytomegalovirus (CMV), 442–444
- D**
- Daclizumab, 402
- DBP. *See* Diastolic blood pressure (DBP)
- DCD. *See* Donation after cardiac death (DCD)
- Death with functioning graft (DWFG), 465
- Delayed graft function (DGF), 463
- Delta anion gap, 124, 128, 129
- Delta–delta ratio, acid–base disorders, 160, 161
- DES. *See* Dialysis disequilibrium syndrome (DES)
- Dexamethasone suppression test (DST), 523
- DGF. *See* Delayed graft function (DGF)
- Diabetes mellitus, 287–289
- Diabetic glomerulopathy, 553–554
- Diabetic kidney disease  
care, 558  
case study, 549–550, 559  
differential diagnosis, 556  
epidemiology, 550  
etiology/pathophysiology, 550  
GFR, 550, 551, 555  
glucose control, 556–557  
K/DOQI guidelines, 555  
kidney biopsy, 555–556  
kidney imaging, 555  
lifestyle changes, 558  
lipid control, 558  
preventive measures/prophylaxis, 558–559  
prognosis and complications, 558  
renin–angiotensin system  
beta blockers, 557  
blood pressure control, 557  
CCBs, 557  
RAAS blockade, 557–558  
retinopathy, 555  
urinalysis, 555  
urine albumin excretion, 550, 551, 553–555
- Diabetic nephropathy (DN), 36, 40  
clinical features, 288, 289  
pathogenesis, 288
- Dialysis disequilibrium syndrome (DES), 341–342
- Diastolic blood pressure (DBP), 509–511

- Dietary approaches to stop hypertension (DASH), 507–508
- Dipstick test  
for hematuria, 45–46  
for proteinuria, 20
- Distal renal tubular acidosis, 649
- Diuresis  
calcium disorders, 108  
renography, urinary tract obstruction, 188
- Diuretics  
for acute kidney injury, 240  
for cardiorenal syndrome, 227  
for edema, 39
- Donation after brain death (DBD), 386
- Donation after cardiac death (DCD), 386, 463, 467
- Donor evaluation, kidney  
ABO blood typing, 391  
case study, 391–392  
contraindications, 391, 393  
guidelines, 391  
histocompatibility testing, 391  
medical evaluation, 391  
psychosocial evaluation, 391  
renal function assessment, 391  
screening, medical comorbidities, 391  
short-term risks, 390
- Drug and toxin induced nephrotoxicity  
case study, 199–200, 206  
causes, 200  
clinical presentation, 204  
crystal induced nephropathies, 203  
endothelial cell injury, 203  
epidemiology, 200  
evaluation and differential diagnosis, 204, 205  
inflammation, 203  
intra-glomerular hemodynamics, change in, 203  
mechanism, clinical features, and treatment of, 201–202  
pathogenesis of nephrotoxic kidney injury, 200–202  
pigment induced kidney injury, 204  
podocytopathies, 204  
prevention and treatment, 204, 206  
tubular cell toxicity, 203
- Dyslipidemia, 293–294  
chronic kidney disease, 256
- E**
- Echogenicity, 8
- Eclampsia, 542
- Edema, in nephrotic syndrome, 38, 39
- Electrocardiogram (ECG) abnormalities, potassium disorders, 89
- Electrolyte disturbances, chronic kidney disease, 257–258
- Electron microscopy (EM), 568  
renal biopsy, 62
- Emergency Medical Treatment and Active Labor Act, 312
- Encapsulating peritoneal sclerosis (EPS), 361
- Encephalopathy, 80
- Endothelial cell injury, drug-induced, 203
- End-stage renal disease (ESRD), 113, 622  
palliative care, in renal disease, 373–375, 378
- Enzyme-linked immunosorbent assay (ELISA), ANCA-associated vasculitis, 71
- Epinephrine, hyperkalemia, 99
- Epithelial sodium channel (ENaC), 527
- Epstein–Barr virus (EBV), 446–448
- Erythrocytes, in urine, 22
- Erythropoietin stimulating agent (ESA), anemia  
continuous erythropoietin receptor activators, 278, 279  
dosing guidelines, 278  
hyporesponsiveness, 279  
side effects, 280  
use of, 278–280
- ESRD. *See* End-stage renal disease (ESRD)
- Essential hypertension, 500
- European Society of Urogenital Radiology, 208
- Everolimus, 613
- Exercise, potassium balance, 88
- Expanded-criteria donor, 386
- Extended-criteria donor, 463, 464, 467
- Extended daily dialysis (EDD), for acute kidney injury, 244
- External potassium balance, 89
- F**
- Fabry disease  
clinical features, 617  
glycosphingolipid, 617  
renal pathology, 617  
treatment, 617
- Familial hyperaldosteronism type II, 524
- Familial hypocalciuric hypercalcemia (FHH), 105
- Fanconi syndrome, 113, 623–624
- Fenoldopam, 539, 540, 542
- Fibrillary glomerulonephritis (FGN), 625
- Fibroblast growth factor-23 (FGF-23), 112
- Fibromuscular dysplasia, 519–520
- Fludrocortisone, for hyperkalemia, 99
- Focal segmental glomerular sclerosis (FSGS), 35, 36
- Fractional excretion of magnesium ( $FE_{Mg}$ ), 110
- Fractional excretion of sodium ( $FE_{Na}$ ), 169, 179, 180
- Free light chain (FLC), 623, 627–628
- G**
- GBM. *See* Glomerular Basement Membrane (GBM)
- GFR. *See* Glomerular filtration rate (GFR)
- Gitelman's syndrome, 97, 110, 497
- Glomerular basement membrane (GBM), 614–615
- Glomerular diseases, serologic testing, 67–74
- Glomerular filtration barrier (GFB), 33
- Glomerular filtration rate (GFR), 6, 136, 252, 253, 255, 257, 550, 551, 555  
calculation  
clearance, 11  
substances for, 11–12  
creatinine-based estimation formulae  
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), 15  
Modification of Diet in Renal Disease (MDRD) study, 14, 15

- metabolic alkalosis, 136
    - and plasma creatinine concentration, 12–13
  - Glomerular hematuria, diagnostic approach, 46
  - Glomerular injury, 168–169
  - Glomerulopathies, 624
  - Glomerulonephritis (GN), 44
    - acute, serologic testing, 68, 69
  - Glomerulus, 11, 12
  - Glucocorticoid-remediable aldosteronism (GRA), 139
  - Glucocorticoid remediable hypertension, 524
  - Glucocorticoids
    - calcium disorders, 108
    - lupus nephritis, 569
  - Glucose
    - control, 556–557
    - intracellular potassium shift, 98, 99
  - Glucosuria, 19–20
  - Glycemic control
    - acute kidney injury, 241
    - chronic kidney disease, 257
  - Glycyrrhetic acid, 523
  - Goodpasture's syndrome, serologic testing, 69
  - Gout/uric acid, 292–293
  - Gravid uterus, 598
  - Gross hematuria, 43, 47
  - Guillain Barre syndrome, 144
- H**
- HDL. *See* High-density lipoprotein (HDL)
  - Heart failure (HF), cardiorenal syndrome, 225
  - Helical computed tomography (CT), urinary tract
    - obstruction, 188
  - Hematuria, 4, 6, 22, 601, 613
    - case study, 44–45, 48
    - causes of, 44
    - diagnostic approach
      - glomerular, 46
      - initial evaluation, 45–46
      - microscopic examination, 46
      - nephrology evaluation, 46–47
      - urology evaluation, 47–48
    - glomerulonephritis and hereditary glomerular disease, 44
    - gross hematuria, 43, 47
    - kidney biopsies, 47
    - microscopic hematuria, 43
    - persistent non-glomerular microscopic hematuria,
      - evaluation of, 47
    - prognosis, 48
    - radiologic imaging, 48
    - urological malignancy, 44
  - Hemodialysis (HD), 586
    - case study, 333
    - challenges, 333
    - complications
      - arrhythmias, 344
      - DES, 341–342
      - dialyzer reactions, 341–342
      - hypotension, 343
      - infections, 343
      - machine-related, 342–343
      - mechanical, 344
      - muscle cramping, 340–341
      - nutrition, 344–345
      - quality of life, 344–345
      - thrombosis, 343, 344
    - epidemiology, 334
    - history, 333
    - hyperkalemia, 100
    - indications for
      - acid–base disturbance, 336–337
      - dialyzable toxins, 339
      - electrolyte disorders, 337–339
      - plasma potassium changes, 338
      - poisoning, 339
      - uremia, 340
      - volume overload, 339
    - intermittent prescription, 336, 337
    - physiology and technology, 334–336
    - restless legs syndrome, 345
    - symptoms, prevalence and severity of, 370, 373
    - for tumor lysis syndrome, 223
    - typical dialysate composition, 334
    - ultrafiltration, 334, 339, 342, 343
  - Hemoglobinuria, 19
  - Hemolysis elevated liver enzymes low platelets (HELLP) syndrome, 599, 604
  - Hemolytic uremic syndrome (HUS), 603
  - Henderson–Hasselbalch equation, 157
  - Hepatitis B virus, 451–452
    - membranoproliferative glomerulonephritis, 581–584, 587, 588
    - membranous nephropathy, 581–583, 587
    - polyarteritis nodosa, 581, 583, 584
  - Hepatitis C virus, 449–451
    - membranoproliferative glomerulonephritis, 581–584, 587, 588
    - membranous nephropathy, 581–583, 587
  - Hepatorenal syndrome (HRS)
    - cardiac dysfunction, 213
    - case study, 211–212, 218
    - causes of acute kidney injury, 215
    - clinical features, 214
    - cytokines and vasoactive mediators, 213
    - definition, 212–213
    - diagnosis, 214–215
    - differential diagnosis, 215
    - incidence, 212
    - intra-abdominal hypertension, 215
    - liver transplantation, 217
    - management, 215–216
    - pathophysiology, 213
    - precipitating factors, 213–214
    - preventive measures, 218
    - prognosis, 217
    - renal replacement therapy, 217
    - renal sympathetic stimulation, 213
    - revised diagnostic criteria, 214
    - splanchnic vasodilation and renal vasoconstriction, 213

- Hepatorenal syndrome (HRS) (*cont.*)  
 subtypes of, 212–213  
 transjugular intrahepatic portosystemic shunt, 216–217  
 vasoconstrictor therapy, 216
- Hereditary nephritis  
 AS, 615–616  
 GBM, 614
- High-density lipoprotein (HDL), 485
- HIV associated nephropathy (HIVAN), 579–585, 588
- HLA. *See* Human leukocyte antigen (HLA)
- HRS. *See* Hepatorenal syndrome (HRS)
- Human immunodeficiency virus (HIV), 449
- Human leukocyte antigen (HLA), 463–464
- Hydronephrosis, radiographic assessment, 187, 188
- 11 $\beta$  Hydroxylase deficiency, 524
- 17- $\alpha$  Hydroxylase deficiency, 524
- Hypercalcemia, 623, 627–629  
 causes of, 104  
 clinical features, 106  
 etiology/pathophysiology, 104–105  
 management, 108  
 work-up of, 107
- Hypercalciuria, 648–649
- Hypercapnia, 145
- Hypercoagulability, 34
- Hypercortisolism, 523
- Hyperkalemia  
 case study, 87, 100–101  
 clinical presentation and consequences, 90  
 definition, 88  
 diagnostic approach and investigation  
 increased potassium load, endogenous/exogenous,  
 93  
 medications, 93  
 reduced urinary potassium excretion, 94–95  
 spurious hyperkalemia (pseudohyperkalemia), 93  
 transcellular redistribution, causes of, 94  
 epidemiology, 88  
 management  
 calcium administration, 97–98  
 intracellular potassium shift, 98, 99  
 removal of potassium from body  
 cation-exchange resins, 99–100  
 diuretics, 99  
 mineralocorticoids, 99  
 plasma/dialysate gradient, 100  
 renal replacement therapy, 100
- Hyperlipidemia, nephrotic syndrome, 38–40
- Hypermagnesemia, 109–111
- Hypernatremia, 80, 81
- Hyperoxaluria, 650–651
- Hyperparathyroidism, 526  
 primary, 104–105
- Hyperphosphatemia, 112–115  
 acute kidney injury, 221
- Hyperpnea, respiratory alkalosis, 152
- Hypertension, 287–289  
 ambulatory blood pressure monitoring, 476–477  
 case study, 473, 505, 512  
 chronic, 499  
 chronic kidney disease, 255–256  
 classification, 474  
 conditioned response, 477  
 definition, 474  
 dietary approaches  
 alcohol, 510–511  
 beneficial effects, 510  
 caffeine, 511  
 DASH, 507–508  
 dietary fiber and protein, 509  
 epidemiologic studies, 506  
 fish oil, 511–512  
 Intersalt study, 506  
 magnesium and calcium intake, 508  
 potassium intake, 508  
 smoking, 511  
 TOHP I and II, 507  
 uric acid and, 509  
 weight loss, 509–510  
 Yanomamo Indians, 506  
 epidemiology, 473–474  
 etiology, 475–476  
 isolated systolic, 477  
 Joint National Committee on prevention, 474  
 lifestyle modifications, 505–506, 512  
 malignant, 477  
 masked, 477  
 non-pharmacologic prescriptions, 499  
 pathophysiology, 474–475  
 pharmacologic treatment, 485–489  
 antihypertensive agents, 489  
 black patients, 485  
 case study, 481  
 combination therapy, 483–484  
 initial drug selection, 482–483  
 pregnancy, 489  
 prehypertension, 481–482  
 therapeutic agents, 484–485  
 preeclampsia, 478  
 pregnancy and, 478  
 primary (*see* Primary hypertension)  
 secondary (*see* Secondary hypertension)  
 severity, 474
- Hypertensive emergencies  
 acute aortic dissection, 538–540  
 acute coronary syndrome, 540–541  
 acute kidney injury, 541–542  
 case study, 536–538  
 definition, 535–536  
 intravenous blood pressure medications, 536–537  
 left ventricular failure and pulmonary edema, 540  
 preeclampsia and eclampsia, 542  
 presentation and findings, 538  
 sympathetic crises, 542–543  
 symptoms, physical, and laboratory findings, 536  
 treatment, 538
- Hypertensive urgency, 535, 537, 538
- Hyperuricemia, 220–221, 656
- Hyperuricosuria, 651
- Hyperventilation, respiratory alkalosis, 152



- Hypervolemia, 5
- Hypervolemic hyponatremia, 81
- Hypoalbuminemia, 104  
nephrotic syndrome, 38
- Hypocalcemia, 104  
clinical features, 106  
etiology/pathophysiology, 105–106
- Hypocitraturia, 649–650
- Hypocomplementemia, nephrotic syndrome, 68
- Hypokalemia, 137, 640, 642, 649, 650, 656  
case study, 87, 101  
clinical presentation and consequences, 89–90  
definition, 87  
diagnostic approach and investigation  
  extrarenal potassium loss, 92  
  medications history, 91  
  renal potassium loss, 92, 93  
  spurious hypokalemia, 92  
  transcellular redistribution, causes of, 92  
epidemiology, 87–88  
management  
  intravenous replacement, 96–97  
  magnesium deficiency and, 97  
  monitoring of potassium level, 95  
  oral/enteral replacement, 96  
  potassium replacement, 95–96  
  potassium salt, 96  
  severe/symptomatic hypokalemia, 96  
metabolic alkalosis, 137  
mild, 87
- Hypomagnesemia, 109–111, 138
- Hyponatremia  
case study, 79, 84  
clinical consequences, 80  
hypervolemic hyponatremia, 81  
hypovolemic hyponatremia, 81  
investigations, 80–81  
management  
  osmotic demyelination syndrome (ODS), 82  
  rate of correction, 83–84  
  vaptan, 84  
normovolemic hyponatremia, 82, 83  
pathophysiology, 79–80  
SIAD, 82, 83
- Hypophosphatemia  
case study, 115  
causes of, 112, 113  
complications, 115  
differential diagnosis, 114  
management, 114  
occurrence mechanisms, 112
- Hypouricemic agents, for tumor lysis syndrome, 222–223
- Hypovolemia, 5
- Hypovolemic hyponatremia, 81
- I**
- ICU. *See* Intensive care unit (ICU)
- Immune complex crescentic glomerulonephritis, 53
- Immune complexes, systemic lupus erythematosus, 563–565
- Immunofluorescence (IF), 61, 62  
  ANCA-associated vasculitis, 71  
  staining, 568
- Immunoglobulin A (IgA) nephropathy, 44
- Immunoglobulins, 622, 625, 627
- Immunosuppression, renal transplant recipient  
adverse effects  
  CNI-induced nephrotoxicity, 405–406  
  corticosteroid minimization, 406  
  induction and maintenance agents, 405  
antibody preparation  
  monoclonal, 402  
  polyclonal, 401–402  
antigen-presenting cells, 398  
B-cells, 399  
case study, 397–398, 409–411  
costs, 408  
history of, 398  
immunological risk transplant recipients, 408  
induction antibodies, 401  
induction therapy, 400  
maintenance  
  anti-metabolites, 404  
  calcineurin inhibitors, 403–404  
  corticosteroids, 404  
  mammalian target of rapamycin inhibitors, 404  
  phase therapy, 400  
malignancy, 408  
mechanism of action, immunosuppressive agents, 400, 401  
monitoring schedule  
  CNI levels, 406, 407  
  KDIGO guideline, 406, 407  
  mammalian target of rapamycin inhibitors, 406, 407  
  mycophenolate mofetil level, 407  
  mycophenolic acid level, 407  
pathophysiology, 398–400  
pharmacological interactions, 406, 407  
post-transplant, 400  
post-transplant diabetes mellitus, 408  
pregnancy, 407–408  
preventative medicine, 408–409  
T-cells  
  differentiation, 399  
  mediated rejection, 398, 399  
  3-signal process, 399–400  
  vaccination recommendations, 409
- Immunosuppressive therapy, 575
- Immunotactoid glomerulopathy (ITG), 625
- In-center nocturnal hemodialysis (INHD), 328
- Indomethacin, 603
- Induction immunosuppression, 400
- Infectious disease, kidney transplantation  
  BK nephropathy (BKN), 439–440  
  BK virus (BKV)  
    case study, 439  
    description, 439  
    DNA testing, 441

- Infectious disease, kidney transplantation (*cont.*)  
 prevalence, 439  
 risk reduction, 440  
 serum assays, 441  
 surveillance protocol, 439  
 case study, 429–430, 438–439  
 central nervous system infection, 453  
 cytomegalovirus (CMV)  
 case study, 444–445  
 clinical trial, 443  
 detection methods, 442  
 diagnosis, 442  
 IMPACT trial, 443–444  
 preemptive treatment strategies, 443, 444  
 seroprevalence, 442  
 treatment, 444  
 universal prophylaxis, 443, 444  
 Epstein–Barr virus (EBV)  
 case study, 445–446, 448–449  
 clinical manifestations, 446  
 description, 446  
 PTLD (*see* Post-transplant lymphoproliferative disorders (PTLD))  
 seroprevalence, 446  
 hepatitis B, 451–452  
 hepatitis C, 449–451  
 human immunodeficiency virus (HIV), 449  
 potential pathogens, exposures to, 437–438  
 respiratory tract infection, 453–454  
 risk factors  
 American Society of Transplantation guidelines, 434, 435  
 anatomic considerations, 432–433  
 antimicrobial prophylaxis, 434  
 characteristics, 430  
 comorbidities, 430–432  
 immune suppressants, 433–434  
 indwelling catheters, 432  
 multiple antibiotics, 435–436  
 perioperative prophylactic antibiotics, 436  
 pre-existing infection and immunity, 434  
 unique susceptibility, 430  
 vaccination, 434–436  
 United States Renal Data System (USRDS), 429  
 Inflammation, drug-induced, 203  
 Inotropes, cardiorenal syndrome, 227  
 Insulin  
 intracellular potassium shift, 98, 99  
 potassium balance, 88  
 Insulin-like growth factor, 610  
 Intensive care unit (ICU), 166  
 Intermittent hemodialysis (IHD), for acute kidney injury, 242  
 Internal potassium balance, 88–89  
 Interstitial injury, 168  
 Interstitial nephritis, 603  
 Intra-abdominal hypertension (IAH), 215  
 Intracellular potassium shift, hyperkalemia, 98, 99  
 Intracranial hemorrhage (ICH), 538  
 Intracranial pressure, 525  
 Intracranial vascular events, 525  
 Intra-glomerular hemodynamics, change in, 203  
 Intrahepatic cholestasis of pregnancy (ICP), 597  
 Intratubular obstruction, 169  
 Intravenous blood pressure medications, 536–537  
 Intravenous push, 130  
 Intravenous pyelography (IVP), 644  
 Intravenous urography (IVU), urinary tract obstruction, 188  
 Iodixanol, 210  
 Iohexol, 210  
 Iopamidol, 210  
 Iothalamate, glomerular filtration rate calculation, 12  
 Iron deficiency anemia  
 diagnosis, 281, 282  
 IV iron formulations, 282, 283  
 oral iron formulations, 282, 284  
 serum ferritin level, 281, 282  
 transferrin saturation, 281, 282  
 Ischemia, acute tubular necrosis, 193–195  
 Isolated systolic hypertension, 477  
 Isosthenuria, 19  
 IVP. *See* Intravenous pyelography (IVP)
- J**  
 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)
- K**  
 Karnofsky Performance score, 312  
 Kayexalate®, 99  
 Ketoacidosis, 160, 161  
 Kidney biopsy, 555–556  
 Kidney Dialysis Outcomes Quality Initiative (KDOQI), 264  
 Kidney disease  
 antiretroviral therapy, 584–585  
 case study, 579, 588, 621, 629–630  
 clinical features, 582, 625–627  
 diagnosis, 582, 583  
 differential diagnosis, 584  
 epidemiology, 580–581, 622  
 etiology and pathophysiology, 581–582  
 FLC, 627–628  
 HBV and HCV associated, 581–587  
 hemodialysis, 586  
 IgM, hyperviscosity, 625  
 immunofixation, 627, 628  
 management, 584  
 M protein, 627  
 pathophysiology, 622  
 preventive measures/prophylaxis, 587  
 prognosis and complications, 586  
 transplantation, 587  
 treatment and outcomes, 628–629  
 tubulointerstitial disorders, 623–625  
 types, 623  
 viral infections, 580  
 Kidney Disease International Global Outcomes (KDIGO), 264

- Kidney Disease Outcomes Quality Initiative (KDOQI), 251, 252, 255, 256
  - Kidney function testing, 594–595
  - Kidney imaging, 555
  - Kidneys, potassium disorders, 90
  - Kidneys, ureters, and bladder (KUB), 643, 644, 652
  - Kidney transplantation, complications of
    - allograft rejection, 415–416
    - case study, 413–414, 416
    - incisional hernia, 415
    - lymphocele, 414–415
    - post-transplant malignancies, 418
    - post-transplant proteinuria, 416–417
    - recurrent glomerulonephritis
      - FSGS, 422, 423
      - IgA nephropathy, 422, 423
      - Kaplan–Meier analysis, 421, 422
      - membranoproliferative glomerulonephritis, 422, 424
      - membranous nephropathy, 422, 424
      - pathological and clinical presentations, 421
      - prevalence, 420
      - prevention and treatment, 421, 422
      - recurrence and allograft loss, risks of, 420, 421
    - surgical, 414
    - urinary tract infection, 418–419
    - urinoma, 414
    - viral infections
      - BK virus, 417–418
      - cytomegalovirus (CMV), 418
      - Epstein–Barr virus (EBV), 418
  - Kidney transplantation, HIV infection, 587
  - Kidney transplant outcomes
    - acute rejection, 463
    - BKVN, 464
    - CAN, 465–466
    - case studies, 461–462
    - CIT, 464
    - CNI, 465
    - DGF, 463
    - donor variables, 467
    - DWFG, 465
    - elderly, 467
    - HLA, 463–464
    - medication adherence, 464
    - post-transplant cancer, 466–467
    - post-transplant metabolic syndrome, 466
    - primary non-function, 463
    - recipient variables, 467–468
    - recurrent disease, 464–465
    - short-term and long-term, 462
  - KUB. *See* Kidneys, ureters, and bladder (KUB)
  - Kupin, W., 119
  - Kussmaul breathing, metabolic acidosis, 123–124
- L**
- Lactic acidosis, 161
  - LCDD. *See* Light chain deposition disease (LCDD)
  - Le Chatelier's principle, respiratory acidosis, 144
  - Left ventricular failure
    - presentation and findings, 540
    - treatment, 540
  - Lenalidomide, 628, 629
  - Lenz, O., 157
  - Leukocyte esterase, 21
  - Leukocytes, in urine, 22
  - Licorice ingestion, 523
  - Liddle syndrome, 527
  - Light chain deposition disease (LCDD), 624, 627
  - Light microscopy, 567
    - stains, of renal biopsy, 61, 62
  - Liver cysts, 609
  - Liver transplantation, hepatorenal syndrome, 217
  - Long-term kidney transplant outcomes, 462
  - Lupus nephritis (LN), serologic testing
    - anti-C1q antibodies, 72–73
    - anti-dsDNA antibodies, 72
    - Farr assay, 72
- M**
- Macroglossia, 627
  - Macrovascular disease, 169
  - Magnesium ammonium phosphate (struvite) stones, 652–653
  - Magnesium disorders
    - case study, 111–112
    - clinical features, 110
    - complications, 111
    - diarrhea, 110
    - differential diagnosis, 110
    - epidemiology, 109
    - etiology/pathophysiology, 109–110
    - Gitelman syndrome, 110
    - hypermagnesemia, 109–111
    - hypomagnesemia, 109–111
    - management, 111
    - renal failure, 111
  - Magnesium dypirone, 603
  - Magnetic resonance imaging (MRI), renal, 27
  - Magnetic resonance urography, urinary tract obstruction, 188
  - Maintenance immunosuppression
    - anti-metabolites, 404
    - calcineurin inhibitors, 403–404
    - corticosteroids, 404
    - mammalian target of rapamycin inhibitors, 404
    - phase therapy, 400
  - Malignant hypertension, 477, 535
  - Masked hypertension, 477
  - Masson trichrome stain, 61, 62
  - Medications, patient assessment, 5
  - Medullary hypoxia, contrast induced nephropathy, 209
  - Melphalan, 629
  - Membranoproliferative glomerulonephritis, 581–584, 587, 588
  - Membranous nephropathy (MN), 36, 581–583, 587
  - Mesangial cell, 624, 625

- Metabolic acidosis, 159–160  
 vs. acidemia, 120  
 algorithm, 131  
 anion gap, 125–126  
 base excess concept, 120  
 blood gas report, 129–130  
 case study, 119, 120, 131–133  
 clinical settings, 122  
 compensatory mechanisms, 123  
 delta anion gap, 124, 128, 129  
 delta gap, 127, 128  
 delta gap ratio, 124, 129  
 diagnosis of, 121–122, 124–125  
 evaluation of, 124–125  
 HCO<sub>3</sub>-measurement, 122  
 Kussmaul breathing, 123–124  
 osmolar gap, 124, 129  
 physiologic concept, 119, 120  
 renal response, 126–127  
 serum K<sup>+</sup> concentration, 130–131  
 strong ion concept, 120  
 systemic complications, 122–123  
 treatment of, 130  
 urine anion gap (UAG), 127, 128
- Metabolic alkalosis, 158–160  
 case studies, 135, 140–141  
 causes of, 136, 137  
 chloride depletion, 137  
 clinical approach and diagnosis, 138–139  
 description, 135  
 differential diagnosis, 136  
 effective arterial blood volume, 136  
 glucocorticoid-remediable aldosteronism (GRA), 139  
 hypokalemia, 137  
 hypomagnesemia, 138  
 mineralocorticoid, 137–138  
 pathophysiology, 135–136  
 reduced glomerular filtration rate, 138  
 renal failure, 138  
 renin–aldosterone axis, disturbances of, 136  
 treatment, 139–140  
 tubular disorders, 138
- MGUS. *See* Monoclonal gammopathy of unknown significance (MGUS)
- Microalbuminuria, 497, 498
- Microscopic examination of urine, 21–23  
 hematuria, 46
- Microscopic hematuria, 43, 47
- Microscopic polyangiitis (MPA), 70
- Microvascular disease, 169
- Microvasculature, acute tubular necrosis, 193
- Midodrine, for hepatorenal syndrome, 216
- Milk-alkali syndrome, 105, 598
- Mineral and bone disorder (MBD), CKD, 257  
 biochemical markers, 263  
 biochemistry  
   calcium, 265  
   fibroblast growth factor 23, 266  
   hyperphosphatemia, 265  
   hypocalcemia, 265  
   parathyroid hormone, 265–266  
   phosphorus, 266  
   vitamin D, 266–267  
 case study, 263, 272  
 complications, 264  
 KDIGO, 264  
 KDOQI, 264  
 management guidelines, 264  
 monitoring recommendations, 267–268  
 treatment  
   calcidiol, 268, 269  
   cinacalcet, 270  
   dietary restriction, 268  
   doxercalciferol, 269, 270  
   parathyroidectomy, 270, 272  
   paricalcitol, 268–270  
   phosphate restriction/binders, 270  
   sevelamer, 270  
   thiosulfate, 272  
   vitamin D 25, 268–269  
   vitamin D analogues, 269–270
- Mineralocorticoid, 137–138  
 hypertension, 521
- Minimal change disease (MCD), 36
- Mixed acid-base disorders. *See* Acid–base disorders, mixed
- Mixed uremic osteodystrophy, 264
- Modification of Diet in Renal Disease (MDRD) study, 14, 15, 252, 255
- Modified Diet in Renal Disease estimate glomerular filtration rate (MDRD eGFR), 317
- Modified Edmonton Symptom Assessment System, 377
- Monoclonal gammopathy of unknown significance (MGUS), 625
- Monocyte chemoattractant protein-1 (MCP-1), 567
- Monotherapy, hypertension, 483–485
- M protein, 622, 625, 627, 628
- Multiple myeloma  
 case study, 621, 629–630  
 clinical features, 625–627  
 description, 621–622  
 diagnostic criteria, 622  
 epidemiology, 622  
 FLC, 627–628  
 IgM, hyperviscosity, 625  
 immunofixation, 627, 628  
 M protein, 627  
 pathophysiology, 622–623  
 treatment and outcomes, 628–629  
 tubulointerstitial disorders, 623–625
- Mutation, autosomal dominant polycystic kidney disease, 608–611
- Mycophenolate mofetil (MMF), 569, 573
- N**
- National Health and Examination Survey (NHANES) III, 122
- National Kidney Foundation’s Kidney Early Evaluation Program (KEEP®), 252, 254

- Nephrocalcinosis, 106, 639–641, 644, 651
- Nephrolithiasis, 45, 598–599
  - abdominal imaging, 643–644
  - acute medical management, 645
  - calcium oxalate and calcium phosphate stones, 648
  - case study, 635, 646
  - clinical presentation, 637
  - creatinine, 642
  - cystine stones, 653
  - diagnostic evaluation of, 639, 640, 646–647
  - dietary modification, 647
  - differential diagnosis, 639
  - distal RTA, 649
  - expulsive medical therapy, 645
  - hypercalciuria, 648–649
  - hyperoxaluria, 650–651
  - hyperuricosuria, 651
  - hypocitraturia, 649–650
  - imaging modalities for, 639, 640, 642–643
  - indications, 646
  - magnesium ammonium phosphate (struvite) stones, 652–653
  - medications, 647–648, 654–656
  - outpatient vs. inpatient management, 645–646
  - pathophysiology
    - cystinuria, 637
    - super saturation, 636
  - risk factors, 637–638
  - serum calcium, 642
  - stone analysis, 644
  - stones types, 636
  - unusual stones, 656
  - uric acid stones, 651–652
  - urinalysis and sediment examination, 641–642
- Nephronophthisis, 618
- Nephrotic syndrome
  - acquired, 35–36
  - case study, 33
  - clinical features, 37
  - congenital, 35
  - differential diagnosis, 35–37
  - edema, 38
  - focal segmental glomerular sclerosis (FSGS), 35, 36
  - hyperlipidemia, 38
  - hypoalbuminemia, 38
  - investigations, diagnostic evaluation, 38, 39
  - kidney transplant patients, 36
  - management
    - edema, 39
    - hyperlipidemia, 39–40
    - proteinuria, 39
  - membranous nephropathy (MN), 36
  - minimal change disease (MCD), 36
  - nephrotic-range proteinuria, 38
  - outcomes, 40
  - pathophysiology, 33–35
  - podocyte effacement and fusion, 35
  - renal biopsy, 36
  - serologic testing, 67
    - acute glomerulonephritis, 68, 69
    - in adults, laboratory tests, 68, 69
    - hypocomplementemia, 68
- Nephrotoxic acute kidney injury, 199–206
- Nephrotoxins, acute tubular necrosis, 192
- Nesiritide, for cardiorenal syndrome, 227
- Neutrophils, in urine, 22
- NIPV. *See* Noninvasive positive pressure ventilation (NIPV)
- Nitric oxide (NO), hepatorenal syndrome, 213
- Nitrites, urinalysis, 21
- Nocturnal home dialysis (NHHD), 328
- Non-Heart-Beating Donors (NHBD), 467
- Noninvasive cardiac stress testing (NCST), 388
- Noninvasive positive pressure ventilation (NIPV), 147
- Norfloxacin, spontaneous bacterial peritonitis, 218
- Normal glomerulus, 552
- Normovolemic hyponatremia, 82, 83
- Nutritional goals, in acute kidney injury, 241
- Nutrition, CKD
  - assessment methods, 300–301
  - case study, 299–300
  - dietary recommendations, 301, 302
  - minerals and electrolytes
    - magnesium, 305
    - phosphorous/calcium/vitamin D, 304–305
    - potassium, 305
    - sodium, 305
    - trace elements, 305–306
  - mortality indicator, 307
  - nutrients
    - calories, 301, 303
    - carbohydrates, 304
    - lipids, 304
    - protein, 303–304
    - vitamins, 306
- O**
- Obesity, 292
- Obstetrical hemorrhage, 596
- Obstructive nephropathy, 184
- Obstructive uropathy, 184
- Octreotide, for hepatorenal syndrome, 216
- Odor, of urine, 19
- OKT3 antibody, renal transplant recipient, 402
- Oliguria, AKI, 168
- OPTN. *See* Organ Procurement and Transplantation Network (OPTN)
- Oral therapy, 130
- Organ Procurement and Transplantation Network (OPTN), 462, 464
- Osmolality
  - potassium balance, 88
  - of urine, 19
  - and vasopressin, hypovolemic hyponatremia, 81
- Osmolar gap, 124, 129
- Osmotic demyelination syndrome (ODS), 82
- Osteitis fibrosis, 264
- Osteomalacia, 264

**P**

- Palliative care, in renal disease. *See* Renal disease, palliative care
- Pamidronate, 108
- Panel reactive antibody (PRA), 390
- Papilledema, 535
- Paraprotein. *See* M protein
- Parathyroidectomy, MBD, 270, 272
- Parathyroid gland, 108
- Parathyroid hormone (PTH), 104, 107–108
- Parathyroid hormone-related protein (PTHrP), 105
- Pauci-immune glomerulonephritis, 53, 59, 60
- Pegylated interferon, 586
- Percutaneous nephrostomy (PCN) tube, 188, 189
- Peripheral vascular resistance, 497
- Peritoneal dialysis (PD), 586–587
  - for acute kidney injury, 244
  - basics of, 350
  - case study, 349–350
  - categories, 355
  - catheter and transfer set, 351, 352
  - catheter placement, 351–352
  - description, 350
  - diffusion and ultrafiltration, 350, 351
  - exit-site care, 352
  - goals of, 350, 351
  - infectious complications
    - exit-site infection, 363
    - peritonitis, 361–363
    - tunnel infections, 363
  - infectious-related indications, 362
  - modalities, 354–355
  - noninfectious complications
    - abdominal wall leaks, 358–359
    - catheter dysfunction, 357–358
    - EPS, 361
    - hemoperitoneum, 359–360
    - hernia formation, 358
    - hydrothorax, 359
    - leaks, 358
    - metabolic, 360
    - pain, 360
    - pericatheter leak, 359
    - ultrafiltration failure, 360, 361
  - peritoneal equilibration test, 353–354
  - prescription details, 355–356
  - solutions, composition of, 352–353
  - volume management, 356–357
- Peritonitis
  - antibiotics, 361, 362
  - case study, 362–363
  - diagnosis, 362
  - epidemiology, 362
  - incidence, 362
  - microbiology, 362
  - organisms causing, 362
- Peurperal sepsis, 601
- PEW. *See* Protein energy wasting (PEW)
- Phentolamine, 537
- Pheochromocytoma, 524–525
- pH, of urine, 19
- Phosphorus disorders
  - case study, 115
  - clinical features, 113–114
  - complications, 115
  - definition, 112
  - differential diagnosis, 114
  - epidemiology, 112
  - etiology/pathophysiology, 112–113
  - Fanconi's syndrome, 113
  - FGF-23, 112
  - hyperphosphatemia, 112–115
  - hypophosphatemia, 112–115
  - management, 114
  - phosphate binders, 114
- Physical exam, patient assessment, 5–6
- Pigment induced kidney injury, 204
- Podocytes
  - effacement and fusion, in nephrotic syndrome, 35
  - in urine, 22
- Polyarteritis nodosa (PAN), 70, 581, 583, 584
- Polycystin, 608–610
- Post-infectious glomerular nephritis, 600
- Post-transplant cancer, 466–467
- Post-transplant lymphoproliferative disorders (PTLD)
  - description, 446
  - diagnosis, 447
  - incidence, 447
  - indirect testing, 447
  - pathology, 447
  - prognosis, 448
  - risk factors, 447
  - therapies, 447–448
  - WHO classification, 446
- Post-transplant metabolic syndrome, 466
- Potassium disorders
  - hyperkalemia
    - case study, 87, 100–101
    - clinical presentation and consequences, 90
    - definition, 88
    - diagnostic approach and investigation, 92–95
    - epidemiology, 88
    - management, 97–100
  - hypokalemia
    - case study, 87, 101
    - clinical presentation and consequences, 89–90
    - definition, 87
    - diagnostic approach and investigation, 91–92
    - epidemiology, 87–88
    - management, 95–97
    - mild, 87
  - laboratory tests, 90
  - physiology/pathophysiology
    - distal nephron, principal cells of, 89
    - external potassium balance, 89
    - internal potassium balance, 88–89
    - total body potassium content, 88
  - transtubular potassium gradient, 90

- Preeclampsia, 542, 599
- Pregnancy
- acquired urinary tract obstruction, 185
  - acute kidney disease, 595
  - acute uric acid nephropathy, 602
  - case study, 593, 604
  - cortical necrosis, 601
  - endogenous toxins
    - SCD, 602
    - uric acid, 602
  - exogenous toxins
    - indomethacin, 603
    - ritodrine, 602
  - hematuria, 601
  - interstitial nephritis, 603
  - kidney function testing, 594–595
  - kidney-related physiology, 594
  - periperal sepsis, 601
  - post-infectious glomerular nephritis, 600
  - post-renal
    - gravid uterus and ureteral obstruction, 598
    - nephrolithiasis, 598–599
  - preeclampsia and HELLP syndrome, 603
  - prerenal
    - AFLP, 596–597
    - cardiomyopathy, 598
    - hyperemesis gravidarum, 596
    - ICP, 597
    - milk alkali syndrome, 598
    - obstetrical hemorrhage, 596
  - proteinuria, 595
  - rhabdomyolysis, 601–602
  - TTP/HUS, 603
- Prehypertension, 474, 478
- Prerenal azotemia, 167–168
- afferent arteriolar vasodilation and efferent arteriolar vasoconstriction, 177, 178
  - autoregulation, 176
  - case study, 175, 181
  - clinical presentation and diagnosis, 177, 178
    - ABUN/creatinine ratio, 179
    - drugs, 178–179
    - FENa, 179, 180
    - laboratory studies, 179
    - therapeutic trial, 180
    - urine studies, 179–180
  - etiology/pathophysiology, 176–177
  - intrarenal hemodynamic patterns, 176, 177
  - management/outcomes, 180
  - reduced renal perfusion, 176
  - renal blood flow (RBF) and GFR stability, mechanisms for, 176
  - renal perfusion pressure, 176, 177
  - renin–angiotensin system, blockade of, 178
  - vasodilatory prostaglandins loss, 178
  - volume depletion, 176–178, 180
- Pressure of alveolar carbon dioxide (PACO<sub>2</sub>), respiratory acidosis, 143–144
- Primary cilium, 610
- Primary hyperaldosteronism, 521–522
- Primary hypertension
- blood pressure, 499
  - case study, 493, 501
  - chronic, 499
  - clinical presentation, 498
  - definition and epidemiology, 493
  - diagnosis
    - blood pressure measurement, 494–495
    - initial evaluation, 496
    - non-dipper vs. dipper, 496
  - history, 498–499
  - pathogenesis
    - blood pressure control physiology, 497
    - environmental or non-genetic factors, 498
    - genetic factors, 497–498
    - pregnancy, 497
  - symptoms and signs, 498
  - treatment, 500–501
- Progressive renal dysfunction, 608
- Pro-hypertensive diet, 494
- Prostaglandin synthetase, 606
- Prostate, urinary tract obstruction and, 185, 187, 188
- Protein energy wasting (PEW)
- calories, 301, 303
  - characterization, 306
  - comorbid conditions, 303
  - magnesium level, 305
  - nontraditional risk factor, 300
  - nutritional status, evaluation of, 300–301
  - treatment of, 306
  - zinc deficiency, 306
- Protein-to-creatinine ratio, 20, 21
- Proteinuria, 6
- chronic kidney disease, 253, 256
  - dipstick, 20
  - glomerular diseases, 21
  - management, nephrotic syndrome, 38, 39
  - qualitative analysis, 21
  - quantitative measurement, 20–21
  - sulfosalicylic acid test, 20
- Pseudohematuria, 46
- Pseudohypertension, 477
- Psychogenic syndrome, 153
- PTLD. *See* Post-transplant lymphoproliferative disorders (PTLD)
- Pulmonary edema
- presentation and findings, 540
  - treatment, 540
- Pulmonary renal syndrome, 5–6, 168
- Purine catabolism pathway, 220
- Q**
- Quadriplegia, 525–526
- R**
- Radionuclide scintigraphy, 28
- Rapamycin, 613

- Rapidly progressive glomerulonephritis (RPGN)  
 case study, 51  
 anti-GBM disease, crescents in, 56, 57  
 cellular crescent and fibrinoid necrosis, ANCA vasculitis, 56  
 follow-up, 56–57  
 immunofluorescence, anti-IgG antibody deposition, 57  
 red blood cell casts, 56  
 causes of, 52  
 characteristics, 52  
 classification  
 frequency of types, 53  
 type I/anti-GBM, 52–53  
 type II/immune complex, 53  
 type III/pauci-immune, 53  
 clinical presentation, 53–54  
 differential diagnosis, 54–55  
 follow-up, 56–57  
 investigations, 54  
 management, 55  
 outcomes, 55–56  
 pathophysiology, 52  
 systemic lupus erythematosus, 564
- Rasburicase, for tumor lysis syndrome, 223
- Recipient evaluation, kidney transplant  
 case study, 385, 390  
 cell-based assays, 390  
 complement-dependent lymphocytotoxicity assay, 390  
 donor-specific antibodies, 389–390  
 flow cytometry, 390  
 histocompatibility testing, 389–390  
 history, 386  
 human leukocyte antigens, 389–390  
 operative risk assessment, 386, 387  
 physical examination, 386  
 psychosocial evaluation, 389  
 renal disease evaluation, 386  
 screening  
 cardiovascular disease, 388  
 infectious disease, 388  
 malignancies, 389  
 solid-phase assays, 390  
 surgical considerations, 386, 388
- Rejection, acute, 463
- Renal artery stenosis, 25, 29
- Renal biopsy  
 acute tubular necrosis, 194–195  
 interpretation of  
 case study, 59, 64  
 clinical and laboratory information, 63  
 critical diagnoses, 63  
 cryoglobulinemia, from case patient, 64  
 indications, 60  
 interpretation and report, 62–64  
 lupus nephritis, classification for, 63  
 purpose, 59–60  
 safety of procedure, 61  
 tissue processing, 61–62  
 value of, 60–61
- Renal blood flow (RBF), prerenal azotemia, 176
- Renal calculi, 654, 656
- Renal cystic disease, 611–612
- Renal cysts, 610
- Renal diagnostic testing approaches  
 case study, 17–18, 23–24, 28–29  
 abdominal pain, 17–18  
 differential diagnosis, 23, 28  
 difficult-to-control hypertension, 18  
 hypertension and coronary artery disease, 17  
 proteinuria, 17  
 renal artery stenosis, 29  
 subnephrotic proteinuria and microscopic hematuria, 24
- imaging, 24  
 arteriography, 27–28  
 computed tomography, 26–27  
 glomerular filtration rate measurement, 27  
 magnetic resonance imaging, 27  
 plain radiography, 26  
 radionuclide scintigraphy, 28  
 renal diseases, 24  
 retrograde pyelography, 26  
 ultrasonography, 25–26
- microscopic examination, 21  
 bacteria, 22  
 casts, 22–23  
 cells, 22  
 crystals, 23  
 patterns and clinical significance, 23, 24
- urinalysis, 18–21
- Renal disease, palliative care  
 advance care planning  
 end-of-life discussions, 376  
 and prognostication, 376  
 prognostic information, 375, 376  
 vs. traditional advance directives, 375
- case study, 367–368
- CKD, 373–375
- dialysis without selection, 369–370  
 and end-of-life care, 378–379
- end-stage renal disease (ESRD)  
 aging population, emergence of, 369–370  
 annualized mortality, 369, 371  
 components of, 374–375  
 dialysis deaths, 369–370  
 functional capacity, 370, 372  
 practicum for, 368–369  
 symptom, 370  
 technology-centered program, 369
- patient-centered care, 370–373
- symptom control, 377–378
- Renal disease, patient assessment  
 case study, 3–4, 8–9  
 laboratory findings, 6–7  
 patient history  
 family history, 5  
 medications, 5  
 systemic diseases, 4–5  
 urologic history, 4  
 volume status, 4



- physical exam
    - abdomen/genitourinary, 6
    - head, 5
    - pulmonary, 5–6
    - skin and joints, 6
    - volume status/cardiovascular, 5
  - secondary causes, 7
  - ultrasound, 7–8
  - Renal function, assessment
    - case study, 11, 14, 15
    - creatinine
      - plasma concentration and glomerular filtration rate, 12–13
      - plasma concentration changes, factors, 13
    - creatinine clearance (CrCl), 14
    - cystatin C, 15–16
    - glomerular filtration rate
      - clearance, 11
      - creatinine-based estimation formulae, 14–15
      - substances, 11–12
    - glomerulus, 11, 12
  - Renal hypoperfusion, acute tubular necrosis, 192
  - Renal-limited vasculitis (RLV), 70
  - Renal osteodystrophy, 264
  - Renal perfusion pressure, prerenal azotemia, 176, 177
  - Renal replacement therapy (RRT)
    - for acute kidney injury
      - advantages and disadvantages, 243
      - considerations in, 243
      - continuous renal replacement therapy, 244, 245
      - diffusion and convection, 242
      - extended daily dialysis, 244
      - in ICU, treatment modality, 242
      - indications for, 243
      - intermittent hemodialysis, 242
      - peritoneal dialysis, 244
      - selection of, 241–242
      - sustained low-efficiency dialysis, 244
    - hepatorenal syndrome, 217
    - hyperkalemia, 100
    - patient counseling
      - autosomal dominant polycystic kidney disease, 325, 329
      - case study, 325, 329–330
      - central venous catheter access, 328
      - dialysis preparation, 327–328
      - end-stage renal disease options, 325–326
      - in-center nocturnal hemodialysis, 328
      - late stage kidney disease, 330
      - modality selection, 328
      - nocturnal home dialysis, 328
      - outcomes, 328
      - palliative care, 329
      - peritoneal dialysis catheter, 329
      - transplantation, consideration of, 326–327
      - vascular access preparation, 328
  - Renal tubular acidosis (RTA), 636, 637, 640–642, 646
  - Renal ultrasound, 644
  - Renin, 90, 91
  - Renin–angiotensin–aldosterone system (RAAS)
    - blockade, 557–558
    - proteinuria, 256
  - Renin–angiotensin system (RAS)
    - beta blockers, 557
    - blockade, 178, 484, 485
    - blood pressure control, 557
    - CCBs, 557
    - RAAS blockade, 557–558
  - Renin producing tumors, 527
  - Renovascular disease, 519
  - Resistant hypertension
    - case study, 544
    - treatment, 543–544
    - white coat, 543
  - Resistive index, 26
  - Respiratory acidosis, 157, 159
    - alveolar hypoventilation, 143–144
    - case study, 143, 147–148
    - diagnosis, 145–146
    - etiology, 144–145
    - pathophysiology, 144–145
    - treatment of, 147
  - Respiratory alkalosis, 159
    - alveolar hyperventilation, 151, 152
    - case study, 151, 155
    - diagnosis, 154–155
    - etiology, 153
    - pathophysiology, 152
    - symptoms of, 153–154
    - treatment, 154–155
  - Respiratory tract infection, 453–454
  - Retinopathy, 555
  - Retrograde pyelography, 26
    - urinary tract obstruction, 188
  - Rhabdomyolysis, 601–602
  - Ribavirin, 586
  - Risk, injury, failure, loss, end-stage (RIFLE) criteria, 166
  - Rituximab, 573
  - RPGN. *See* Rapidly progressive glomerulonephritis (RPGN)
  - RTA. *See* Renal tubular acidosis (RTA)
- S**
- Saline diuresis, calcium disorders, 108
  - SBP. *See* Systolic blood pressure (SBP)
  - Scientific Registry of Transplant Recipients (SRTR), 462, 464
  - Secondary hypertension
    - ACE inhibitor, 528, 529
    - ARAS, 520–521
    - case study, 517
    - causes
      - coarctation of aorta, 527–528
      - medications associated with, 528, 529
      - sleep apnea, 528
  - CKD, 519
  - Cushing syndrome, 522–523
  - diagnosis, 528–530
  - fibromuscular dysplasia, 519–520

- Secondary hypertension (*cont.*)  
 genetic causes, 527  
 medical causes, 518  
 mineralocorticoid associated, 521  
 neuroendocrine and neurologic causes  
 acromegaly, 526–527  
 endocrine causes, 526  
 hyperparathyroidism, 526  
 intracranial pressure and intracranial vascular events, 525  
 pheochromocytoma, 524–525  
 quadriplegia, 525–526  
 renin producing tumors, 527  
 thyroid disorders, 526  
 primary hyperaldosteronism, 521–522  
 renovascular disease, 519  
 steroid metabolism disorders  
 apparent mineralocorticoid excess, 523–524  
 congenital adrenal hyperplasia, 524  
 familial hyperaldosteronism type II, 524  
 glucocorticoid remediable, 524  
 licorice ingestion, 523
- Sensorineural deafness, 616
- Sepsis, 177, 180  
 acute tubular necrosis, 194, 195
- Serologic testing, in glomerular diseases  
 in ANCA-associated vasculitis, 70  
 assays, 71  
 and disease flares, 71–72  
 in anti-glomerular basement membrane disease, 69  
 antiphospholipid Ab syndrome (APLS), 73  
 case study, 67, 73  
 lupus nephritis, 72–73  
 nephrotic syndrome  
 acute glomerulonephritis, 68, 69  
 in adults, laboratory tests, 68, 69  
 hypocomplementemia, 68
- Serum anion gap, acid–base disorders, 160
- Serum calcium, 642
- Serum creatinine, 170
- Shafazand, S., 143, 151
- Short-term kidney transplant outcomes, 462
- SIAD. *See* Syndrome of inappropriate antidiuresis (SIAD)
- Sickle cell disease (SCD), 602
- Silent killer. *See* Hypertension
- Silver stain, 61, 62
- Sirolimus, 404, 613
- Skeletal muscle weakness, potassium disorders, 90
- Sleep apnea, 528
- Sodium bicarbonate, intracellular potassium shift, 98, 99
- Sodium polystyrene sulfonate, hyperkalemia, 99
- Soft tissue calcification, 264
- Specific gravity, of urine, 19
- Spurious hyperkalemia, 93
- SRTR. *See* Scientific registry of transplant recipients (SRTR)
- Staghorn calculi, 643, 652, 653
- Standard-criteria donor (SCD), 386
- Statins, 293, 294
- Steroid metabolism disorders  
 apparent mineralocorticoid excess, 523–524  
 congenital adrenal hyperplasia, 524  
 familial hyperaldosteronism Type II, 524  
 glucocorticoid remediable, 524  
 licorice ingestion, 523
- Subendothelial deposits, lupus erythematosus, 563, 568
- Sub-epithelial space, lupus erythematosus, 568
- Sulfosalicylic acid test, for proteinuria, 20
- Sustained low-efficiency dialysis (SLED), for acute kidney injury, 244
- Sympathetic nervous system, potassium balance, 88
- Syndrome of inappropriate antidiuresis (SIAD)  
 definition, 82  
 diagnostic criteria, 82  
 drugs, 82
- Systemic diseases, patient assessment, 4–5
- Systemic lupus erythematosus (SLE), 54, 55  
 ACR, 565–566  
 anti-chromatin antibodies, 566  
 anti-C1q antibodies, 567  
 autoantibody specificities, 565–566  
 case study  
 ANA, 563  
 endocapillary, 563  
 subendothelial, 563  
 class V treatment, 574–575  
 clinical pathologic correlations, 565–566  
 decreasing risk, 576  
 differential diagnosis, 568  
 epidemiology, 564  
 etiology/pathophysiology, 564–565  
 glucocorticoid therapy, 569  
 immunosuppression, 574  
 immunosuppressive therapy, 575  
 ISN/RPS classification, 568  
 MMF, 569, 573, 574  
 non-immunomodulatory treatment, 568–569  
 pulsed cyclophosphamide  
 clinical trials, 570–572  
 non-immunosuppressive treatment, 573  
 rituximab, 573  
 serologic testing, 72, 73  
 tacrolimus, 573–574  
 treatment, 568  
 urinary biomarkers, 567
- Systolic blood pressure (SBP), 509–511
- T**
- Tachypnea, respiratory alkalosis, 152
- Tacrolimus, 403, 573–574
- Tamm–Horsfall protein (THP), 623
- Target organ damage (TOD), 535
- Terlipressin, for hepatorenal syndrome, 216
- Thalidomide, 628, 629
- Thiazide diuretics, 485, 489

- Thin basement membrane nephropathy (TBMN), 44, 45  
 clinical features, 616  
 genetics, 616  
 renal pathology, 616–617  
 treatment, 617
- Thrombocytopenic purpura (TTP), 603
- Thymoglobulin, 401, 402
- Tissue processing, renal biopsy, 61–62
- TLS. *See* Tumor lysis syndrome (TLS)
- TNF-like weak inducer of apoptosis (TWEAK), 567
- Tolvaptan, 613  
 hyponatremia, 84
- Tolwani, A.J., 165
- Toonkel, R., 151
- Toxins, acute tubular necrosis, 192
- Transjugular intrahepatic portosystemic shunt (TIPS), 216–217
- Transtubular potassium gradient (TTKG), 90, 94
- Trials of Hypertension Prevention (TOHP), 507
- Triple phosphate crystals, 641
- Tubular cells  
 toxicity, 203  
 in urine, 22
- Tubular changes, acute tubular necrosis, 193
- Tubular injury, 168
- Tumor lysis syndrome (TLS), 169  
 case study, 219  
 Burkitt lymphoma, 224  
 clinical features, 221  
 diagnosis, 221  
 electrolyte management, 223  
 epidemiology, 220  
 hemodialysis, 223  
 hyperphosphatemia, 221  
 hyperuricemia, 220–221  
 hypouricemic agents, 222–223  
 laboratory and clinical, Cairo and Bishop definition of, 221  
 management and preventive measures, 221, 222  
 metabolic derangements, 219  
 pathophysiology, 220  
 patient risk stratification, 222  
 prognosis, 224  
 volume expansion, 221–222
- U**
- Ultrasound  
 bladder, 26  
 contour of kidney, exophytic mass, 26  
 echotexture, 25  
 kidney size, 25  
 renal calculi and cysts, 25  
 renal disease, patient assessment, 7–8  
 renal vasculature, 25–26  
 solid renal mass, 25, 26  
 urinary obstruction, 25  
 urinary tract obstruction, 187–188
- Urea splitting organisms, 641, 652
- Ureteral obstruction, 598
- Uric acid, 509  
 crystals, 642  
 stones, 651–652
- Urinalysis, 6, 555  
 acute tubular necrosis, 194  
 bile pigments, 21  
 color, 18  
 glucose, 19–20  
 hematuria, 45–48  
 hemoglobin, 19  
 ketones, 21  
 leukocyte esterase, 21  
 nitrites, 21  
 odor, 19  
 osmolality, 19  
 pH, 19  
 protein, 20–21  
 specific gravity, 19  
 turbidity, 18–19  
 urine collection, 18
- Urinary biomarkers, 567
- Urinary citrate, 636, 637, 648–651
- Urinary obstruction, ultrasound, 8, 25
- Urinary tract infection (UTI), 418–419
- Urinary tract obstruction (UTO)  
 acquired causes  
 congenital causes, 185  
 extrinsic causes, 185  
 intrinsic causes, intraluminal and intramural processes, 184–185  
 case study, 183, 189  
 clinical presentation and diagnosis, 186–187  
 epidemiology, 184  
 management  
 specific therapy, 188  
 volume and electrolyte management, 188–189  
 obstructive nephropathy, 184  
 obstructive uropathy, 184  
 pathophysiology  
 abnormal acidification, 186  
 vasoconstrictors and vasodilators imbalance, 185  
 prognosis, 189  
 radiologic evaluation, 187–188
- Urinary uric acid excretion, 485
- Urine albumin excretion, 551–555
- Urine alkalization, 647, 651, 653
- Urine anion gap (UAG), metabolic acidosis, 127, 128
- Urine free water loss, 83
- Urologic history, patient assessment, 4
- V**
- Vaptan, hyponatremia, 84
- Vascular abnormalities, acute tubular necrosis, 192–193
- Vascular injury, 169
- Vasoconstrictor therapy, hepatorenal syndrome, 216
- Vasopressin, 240, 609–611, 613
- Vasopressors, for acute kidney injury, 240

**Viral infections**

- antiretroviral therapy, 584–585
  - and associated renal disorders, 580
  - case study, 579, 588
  - clinical features, 582
  - diagnosis, 582, 583
  - differential diagnosis, 584
  - epidemiology, 580–581
  - etiology and pathophysiology, 580–581
  - HBV and HCV associated, 581–587
  - hemodialysis, 586
  - kidney transplantation, 587
  - management, 584
  - peritoneal dialysis, 586–587
  - prevalence, 583
  - preventive measures/prophylaxis, 587
  - prognosis and complications, 586
- Vitamin D, calcium disorders, 105

- Volume expansion, tumor lysis syndrome, 221–222
- Volume resuscitation, acute kidney injury, 239
- Volume status, patient assessment, 4, 5

**W**

- Waldenström's macroglobulinemia (WM), 625
- Wegener's granulomatosis (WG), 5, 55, 56, 70
- White coat hypertension, 476, 477, 543
- Winter's formula, metabolic acidosis, 124

**X**

- Xanthinuria, 656

**Z**

- Zoledronate, 108